All In Biotech

Drug Trial Radar · NCT00447759

The Standard Care Versus Celecoxib Outcome Trial

Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's

Last checked: Nov 19, 2026Latest source record: May 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 7,297 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,297

Actual

Start

Jun 2007

Primary completion

Aug 2015

Study completion Aug 2015

Sponsor

Lead sponsor
University of DundeeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Glasgow; University of Nottingham
First posted
Mar 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Standard Care versus Celecoxib Outcome Trial (SCOT) is a large streamline safety study designed to compare the cardiovascular safety of celecoxib versus traditional non-selective Non Steroidal Anti-Inflammatory Drug (NSAID) therapy.Traditional NSAID's are associated with significant morbidity and mortality from gastrointestinal toxicity. Cyclooxygenase 2 (Cox-2)selective agents are associated with reduced upper gastrointestinal toxicity.Traditional NSAID's and Cox-2 inhibitors may also be associated with cardiovascular and renal disorders. Data from both randomised and observational studies suggest that celecoxib has similar or reduced cardiovascular toxicity when compared to traditional NSAID's. However, the overall safety balance of a strategy of celecoxib therapy versus a strategy of NSAID therapy is unknown. The European Medicines Evaluation Agency (EMEA) has requested that studies of the cardiovascular safety of celecoxib be carried out within the indicated population of Europe. This study addresses these issues by comparing the cardiovascular safety of celecoxib therapy with traditional NSAID therapy in the setting of the EU healthcare system. As of May 2013, 7300 patients had been randomised, and had accrued an average 4.2 years of follow up by the end of May 2014.

Conditions

  • Osteoarthritis
  • Rheumatoid Arthritis

Interventions

  • CelecoxibDrug

    200-400mg daily in divided doses

  • DiclofenacDrug

    prescribed medication taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. compare cardiovascular safety of celecoxib and traditional NSAIDs prescribed for the treatment of arthritis.Time frame: 4 years

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Southern Denmark

    Odense, Denmark

  • Julius Clinical Research

    Zeist, Netherlands

  • University of Aberdeen

    Aberdeen, United Kingdom

  • University of Birmingham

    Birmingham, United Kingdom

  • University of Dundee

    Dundee, United Kingdom

  • University of Edinburgh

    Edinburgh, United Kingdom

  • University of Glasgow

    Glasgow, United Kingdom

  • NHS Highlands

    Inverness, United Kingdom

  • University of Nottingham

    Nottingham, United Kingdom

  • University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.